These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27708090)

  • 21. Alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson's disease.
    Kim S; Jeon BS; Heo C; Im PS; Ahn TB; Seo JH; Kim HS; Park CH; Choi SH; Cho SH; Lee WJ; Suh YH
    FASEB J; 2004 Oct; 18(13):1615-7. PubMed ID: 15289452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enzyme-linked immunosorbent assays for α-synuclein with species and multimeric state specificities.
    Lee HJ; Bae EJ; Jang A; Ho DH; Cho ED; Suk JE; Yun YM; Lee SJ
    J Neurosci Methods; 2011 Aug; 199(2):249-57. PubMed ID: 21658411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
    Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
    Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease.
    Lastres-Becker I; Ulusoy A; Innamorato NG; Sahin G; Rábano A; Kirik D; Cuadrado A
    Hum Mol Genet; 2012 Jul; 21(14):3173-92. PubMed ID: 22513881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. alpha-Synuclein--a link between Parkinson and Alzheimer diseases?
    Heintz N; Zoghbi H
    Nat Genet; 1997 Aug; 16(4):325-7. PubMed ID: 9241262
    [No Abstract]   [Full Text] [Related]  

  • 26. FBXO7 immunoreactivity in α-synuclein-containing inclusions in Parkinson disease and multiple system atrophy.
    Zhao T; Severijnen LA; van der Weiden M; Zheng PP; Oostra BA; Hukema RK; Willemsen R; Kros JM; Bonifati V
    J Neuropathol Exp Neurol; 2013 Jun; 72(6):482-8. PubMed ID: 23656991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrabody and Parkinson's disease.
    Zhou C; Przedborski S
    Biochim Biophys Acta; 2009 Jul; 1792(7):634-42. PubMed ID: 18834937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease.
    Chung KK; Zhang Y; Lim KL; Tanaka Y; Huang H; Gao J; Ross CA; Dawson VL; Dawson TM
    Nat Med; 2001 Oct; 7(10):1144-50. PubMed ID: 11590439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study on exons 3 and 4 of alpha-synuclein gene in Chinese familial Parkinson disease patients].
    Chen X; Liu YT; Li JR; Chen L; Xu YM; Pan YH; Meng XH; Xing SH
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Dec; 20(6):536-8. PubMed ID: 14669226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.
    Sengupta U; Guerrero-Muñoz MJ; Castillo-Carranza DL; Lasagna-Reeves CA; Gerson JE; Paulucci-Holthauzen AA; Krishnamurthy S; Farhed M; Jackson GR; Kayed R
    Biol Psychiatry; 2015 Nov; 78(10):672-83. PubMed ID: 25676491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders.
    Krüger R; Müller T; Riess O
    J Neural Transm (Vienna); 2000; 107(1):31-40. PubMed ID: 10809401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting alpha-synuclein in Parkinson's disease.
    Kapurniotu A
    Chem Biol; 2004 Nov; 11(11):1476-8. PubMed ID: 15555995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha-synuclein in Lewy bodies.
    Spillantini MG; Schmidt ML; Lee VM; Trojanowski JQ; Jakes R; Goedert M
    Nature; 1997 Aug; 388(6645):839-40. PubMed ID: 9278044
    [No Abstract]   [Full Text] [Related]  

  • 34. Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies.
    Brudek T; Winge K; Folke J; Christensen S; Fog K; Pakkenberg B; Pedersen LØ
    Mol Neurodegener; 2017 Jun; 12(1):44. PubMed ID: 28592329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha-synuclein in Parkinson's disease: light from two new angles.
    Golbe LI; Mouradian MM
    Ann Neurol; 2004 Feb; 55(2):153-6. PubMed ID: 14755715
    [No Abstract]   [Full Text] [Related]  

  • 36. Anti-oligomeric single chain variable domain antibody differentially affects huntingtin and alpha-synuclein aggregates.
    Nannenga BL; Zameer A; Sierks MR
    FEBS Lett; 2008 Feb; 582(4):517-22. PubMed ID: 18230361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of alpha-synuclein and its significance].
    Nonaka T; Iwatsubo T; Hasegawa M
    Nihon Rinsho; 2004 Sep; 62(9):1623-8. PubMed ID: 15462375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease.
    Chen L; Feany MB
    Nat Neurosci; 2005 May; 8(5):657-63. PubMed ID: 15834418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
    Volles MJ; Lansbury PT
    Biochemistry; 2003 Jul; 42(26):7871-8. PubMed ID: 12834338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination for Parkinson's disease.
    Schneeberger A; Mandler M; Mattner F; Schmidt W
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S11-3. PubMed ID: 22166404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.